Penicillamine has FDA approval as a treatment for Wilson disease and cystinuria. It is used as an off-label treatment option for lead poisoning in children. It is considered a conventional disease-modifying antirheumatic drug (DMARD). This activity presents penicillamine's indications, contraindications, and side effects and highlights the interprofessional team's role in managing patients with Wilson disease and lead poisoning.

**Objectives:**
- Identify the mechanism of action of penicillamine.
- Describe the adverse effects of penicillamine.
- Summarize the contraindications of penicillamine.
- Outline interprofessional team strategies for improving care coordination and communication to advance the treatment of lead poisoning with penicillamine and improve outcomes.